Welcome to the Schizophrenia Resource Centre

Welcome, this website is intended for healthcare professionals in EMEA with an interest in the treatment of schizophrenia. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

Donald Goff, MD, is interviewed at APA 2014 on new developments in schizophrenia

Whilst there have been disappointments with the withdrawal of two promising glutamatergic agents from development, Dr Goff notes that there have also been encouraging findings. He cites his recently published study on how genes that are involved in the absorption of folate can predict patients treatment response to folate supplementation. He details other innovative and promising approaches such as combining drugs that enhance neuroplasticity with psychosocial interventions, to reduce negative symptoms.

See more content about Genetics, Non-dopaminergic treatments, Psychosocial interventions